Enumeral Biomedical (ENUM) 0.3300 $ENUM
Enumeral to Present at the Emerging Concepts in Host Response to Cancer Symposium at The University of Texas MD Anderson Cancer Center
Business Wire - Mon Oct 05, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that the company will present a poster titled "Human Tumor-Based Identification of Immune Checkpoint Targets" at The University of Texas MD Anderson Cancer Center's Emerging Concepts in Host Response to Cancer Symposium Symposia. Enumeral's poster will highlight recent developments in the company's PD-1 and TIM-3 antibody programs. The poster will be presented at MD Anderson Cancer Center's R. Lee Clark Clinic, 1515 Holcombe Boulevard, Floor 11, in Houston, Texas on October 8, 2015.
Enumeral Announces Identification of Anti-PD-1 Antibodies with Potential for Differentiated Mechanism of Action
Business Wire - Thu Sep 24, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced important progress in its anti-PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company's R&D pipeline, including its TIM-3 and LAG-3 antibody programs.
Enumeral to Present at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference and BioPharm America 2015
Business Wire - Fri Sep 11, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Enumeral will present a poster titled "Human Tumor-Based Identification of Immune Checkpoint Targets" at the International Cancer Immunotherapy Conference. Enumeral's poster will highlight recent developments in the company's PD-1 and TIM-3 antibody programs. The poster number is B083, and will be presented in the Empire Ballroom at the Sheraton New York Times Square Hotel in New York City from 4:45 pm to 6:45 pm on September 18, 2015.
Enumeral Achieves First Milestone in Merck Collaboration
Business Wire - Tue Sep 08, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that it has achieved the first milestone in its immuno-oncology-focused collaboration with Merck Sharp & Dohme Corp. (Merck). In this collaboration, the parties are applying Enumeral's Human Approach immune profiling technology to colorectal cancer patient tissues in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. In accordance with the terms of the December 2014 agreement, Enumeral is to receive a milestone payment from Merck. Enumeral is also eligible to receive undisclosed future milestone payments if certain goals are achieved.
MRK: 50.95 (-0.07)
Enumeral Reports Second Quarter 2015 Financial Results
Business Wire - Wed Aug 12, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended June 30, 2015.
Enumeral Appoints Robert J. Easton to its Board of Directors
Business Wire - Thu Jul 30, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that it has appointed Robert J. Easton to its Board of Directors. Mr. Easton is a recognized leader in the life sciences and healthcare industries, having led strategy development and supervised opportunity assessments for hundreds of clients across the globe, including large and specialty pharmaceutical companies, early-stage and publicly traded biopharmaceutical companies, and diagnostics businesses. Mr. Easton currently serves as Co-Chairman of Bionest Partners, Inc., a consulting firm he co-founded that specializes in strategic planning for pharmaceutical, medical device and diagnostic companies.
Enumeral Announces Progress in PD-1, TIM-3 and Other Pipeline Programs
Business Wire - Tue Jul 14, 7:45AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced recent progress in its PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company's R&D pipeline, including its TIM-3 antibody program.
Enumeral to Participate in Immuno-Oncology Panel at the Cantor Fitzgerald Inaugural Healthcare Conference
Business Wire - Wed Jul 01, 7:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer of Enumeral, will participate in a panel discussion, titled "Continued Opportunities in Immuno-Oncology; Exploring Next-Generation Checkpoint Inhibition," at the Cantor Fitzgerald Inaugural Healthcare Conference, to be held at Le Parker Meridien Hotel in New York City on Wednesday, July 8, 2015 at 11:15 AM ET.
Enumeral Biomedical Is An Overlooked Player In Immuno-Oncology
David Bautz - at Seeking Alpha - Mon Jun 29, 1:47PM CDT
Enumeral Expands Scientific Advisory Board to Support Development of Novel Immunomodulators
Business Wire - Thu Jun 04, 6:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of Giulio Draetta, M.D., Ph.D., and Kai Wucherpfennig, M.D., Ph.D., recognized leaders in the fields of tumor biology and cancer immunotherapy. Enumeral is applying its proprietary immune profiling technology to enable the development of potential best-in-class antibodies against targets in immuno-oncology and other disease applications. The Company's lead program is focused on a next-generation PD-1 antibody, which is expected to enter clinical testing in 2016.
Enumeral Reports First Quarter 2015 Financial Results
Business Wire - Fri May 15, 6:12AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company" , a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended March 31, 2015.
MRK: 50.95 (-0.07)
Enumeral Reports Fourth Quarter and Year-End 2014 Financial Results
Business Wire - Thu Mar 19, 4:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company" , a biotechnology company focused on the discovery and development of novel therapeutics that help the immune system fight cancer and other diseases, today announced its financial results for the three months and full year ended December 31, 2014.
MRK: 50.95 (-0.07)
Enumeral to Present Corporate and Program Overview at March Conferences
Business Wire - Tue Mar 17, 6:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present a corporate overview at BioCentury's 22nd Annual Future Leaders in the Biotech Industry conference on March 20, 2015 at 4:00 p.m. EDT. The presentation will be followed by a breakout session. The meeting is being held at the Millennium Broadway Hotel & Conference Center in New York. A live webcast of the presentation will be accessible on the Events page of Enumeral's website. It will be archived and available for replay for at least 60 days.
Enumeral and the Ragon Institute of MGH, MIT and Harvard to Research Human Mucosal Immunology with Immune Profiling System
Business Wire - Mon Mar 09, 6:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that the company signed an agreement with the Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard University as part of Enumeral's Phase II Small Business Innovation Research (SBIR) contract with the National Cancer Institute (NCI). Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed in the laboratory of Douglas S. Kwon, M.D., Ph.D., Assistant Professor of Medicine at the Ragon Institute. Enumeral recently announced an agreement to place the system with Memorial Sloan-Kettering Cancer Center.
Enumeral to Present at Sachs Associates Cancer Bio Partnering & Investment Forum
Business Wire - Thu Feb 19, 7:01AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present at the Sachs Associates Cancer Bio Partnering & Investment Forum on February 23, 2015 at 12:00 p.m. EST. The meeting is being held at the New York Academy of Sciences in New York City.
Enumeral and Memorial Sloan Kettering Cancer Center to Research Cancer Immunology With Advanced Prototype System for Human Tissue Immuno-Oncology Profiling
Business Wire - Mon Jan 12, 7:02AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that the company signed an agreement with Memorial Sloan Kettering (MSK) Cancer Center as part of Enumeral's Phase II Small Business Innovation Research (SBIR) contract with the National Cancer Institute (NCI). Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed at MSK in the laboratory of Jedd D. Wolchok, M.D., Ph.D., Chief of Melanoma and Immunotherapeutics Service, Lloyd J. Old/Ludwig Chair in Clinical Investigation Department of Medicine and Ludwig Center, at Memorial Sloan Kettering Cancer Center. Dr. Wolchok played a critical role in the clinical development of ipilimumab and nivolumab, immunotherapies which represent a transformational advancement in the treatment of cancer.
Enumeral to Present at Upcoming Conferences in January
Business Wire - Thu Jan 08, 7:01AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present at the following conferences:
Harris & Harris Group Notes Publicly Traded Portfolio Company Enumeral Biomedical's Collaboration With Merck
GlobeNewswire - Mon Dec 22, 11:28AM CST
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes that its publicly traded portfolio company, Enumeral Biomedical Holdings, Inc., announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. Enumeral's human-driven immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response. Under the terms of the agreement, Enumeral will receive R&D funding and is eligible to receive undisclosed future milestone payments if certain goals are achieved. Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies. You may access Enumeral's press release at http://www.enumeral.com/news-events/pr-2014-12-18.php.
TINY: 2.16 (unch), MRK: 50.95 (-0.07)
Enumeral and Merck Form Collaboration for Predicting Clinical Drug Response with Human-driven Immune Profiling Platform
Business Wire - Thu Dec 18, 7:01AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), today announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck.
MRK: 50.95 (-0.07)
Enumeral: An Undiscovered And Undervalued Biotechnology Company
Tony Schwartz, PhD - at Seeking Alpha - Sat Dec 06, 7:00AM CST
Enumeral to Present at the Emerging Concepts in Host Response to Cancer Symposium at The University of Texas MD Anderson Cancer Center
Business Wire - Mon Oct 05, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that the company will present a poster titled "Human Tumor-Based Identification of Immune Checkpoint Targets" at The University of Texas MD Anderson Cancer Center's Emerging Concepts in Host Response to Cancer Symposium Symposia. Enumeral's poster will highlight recent developments in the company's PD-1 and TIM-3 antibody programs. The poster will be presented at MD Anderson Cancer Center's R. Lee Clark Clinic, 1515 Holcombe Boulevard, Floor 11, in Houston, Texas on October 8, 2015.
Enumeral Announces Identification of Anti-PD-1 Antibodies with Potential for Differentiated Mechanism of Action
Business Wire - Thu Sep 24, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced important progress in its anti-PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company's R&D pipeline, including its TIM-3 and LAG-3 antibody programs.
Enumeral to Present at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference and BioPharm America 2015
Business Wire - Fri Sep 11, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Enumeral will present a poster titled "Human Tumor-Based Identification of Immune Checkpoint Targets" at the International Cancer Immunotherapy Conference. Enumeral's poster will highlight recent developments in the company's PD-1 and TIM-3 antibody programs. The poster number is B083, and will be presented in the Empire Ballroom at the Sheraton New York Times Square Hotel in New York City from 4:45 pm to 6:45 pm on September 18, 2015.
Enumeral Achieves First Milestone in Merck Collaboration
Business Wire - Tue Sep 08, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that it has achieved the first milestone in its immuno-oncology-focused collaboration with Merck Sharp & Dohme Corp. (Merck). In this collaboration, the parties are applying Enumeral's Human Approach immune profiling technology to colorectal cancer patient tissues in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. In accordance with the terms of the December 2014 agreement, Enumeral is to receive a milestone payment from Merck. Enumeral is also eligible to receive undisclosed future milestone payments if certain goals are achieved.
MRK: 50.95 (-0.07)
Enumeral Reports Second Quarter 2015 Financial Results
Business Wire - Wed Aug 12, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended June 30, 2015. Enumeral Appoints Robert J. Easton to its Board of Directors
Business Wire - Thu Jul 30, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that it has appointed Robert J. Easton to its Board of Directors. Mr. Easton is a recognized leader in the life sciences and healthcare industries, having led strategy development and supervised opportunity assessments for hundreds of clients across the globe, including large and specialty pharmaceutical companies, early-stage and publicly traded biopharmaceutical companies, and diagnostics businesses. Mr. Easton currently serves as Co-Chairman of Bionest Partners, Inc., a consulting firm he co-founded that specializes in strategic planning for pharmaceutical, medical device and diagnostic companies.
Enumeral Announces Progress in PD-1, TIM-3 and Other Pipeline Programs
Business Wire - Tue Jul 14, 7:45AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced recent progress in its PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company's R&D pipeline, including its TIM-3 antibody program.
Enumeral to Participate in Immuno-Oncology Panel at the Cantor Fitzgerald Inaugural Healthcare Conference
Business Wire - Wed Jul 01, 7:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer of Enumeral, will participate in a panel discussion, titled "Continued Opportunities in Immuno-Oncology; Exploring Next-Generation Checkpoint Inhibition," at the Cantor Fitzgerald Inaugural Healthcare Conference, to be held at Le Parker Meridien Hotel in New York City on Wednesday, July 8, 2015 at 11:15 AM ET.
Enumeral Biomedical Is An Overlooked Player In Immuno-Oncology
David Bautz - at Seeking Alpha - Mon Jun 29, 1:47PM CDT
Enumeral Expands Scientific Advisory Board to Support Development of Novel Immunomodulators
Business Wire - Thu Jun 04, 6:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of Giulio Draetta, M.D., Ph.D., and Kai Wucherpfennig, M.D., Ph.D., recognized leaders in the fields of tumor biology and cancer immunotherapy. Enumeral is applying its proprietary immune profiling technology to enable the development of potential best-in-class antibodies against targets in immuno-oncology and other disease applications. The Company's lead program is focused on a next-generation PD-1 antibody, which is expected to enter clinical testing in 2016.
Enumeral Reports First Quarter 2015 Financial Results
Business Wire - Fri May 15, 6:12AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended March 31, 2015. MRK: 50.95 (-0.07)
Enumeral Reports Fourth Quarter and Year-End 2014 Financial Results
Business Wire - Thu Mar 19, 4:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on the discovery and development of novel therapeutics that help the immune system fight cancer and other diseases, today announced its financial results for the three months and full year ended December 31, 2014. MRK: 50.95 (-0.07)
Enumeral to Present Corporate and Program Overview at March Conferences
Business Wire - Tue Mar 17, 6:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present a corporate overview at BioCentury's 22nd Annual Future Leaders in the Biotech Industry conference on March 20, 2015 at 4:00 p.m. EDT. The presentation will be followed by a breakout session. The meeting is being held at the Millennium Broadway Hotel & Conference Center in New York. A live webcast of the presentation will be accessible on the Events page of Enumeral's website. It will be archived and available for replay for at least 60 days.
Enumeral and the Ragon Institute of MGH, MIT and Harvard to Research Human Mucosal Immunology with Immune Profiling System
Business Wire - Mon Mar 09, 6:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that the company signed an agreement with the Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard University as part of Enumeral's Phase II Small Business Innovation Research (SBIR) contract with the National Cancer Institute (NCI). Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed in the laboratory of Douglas S. Kwon, M.D., Ph.D., Assistant Professor of Medicine at the Ragon Institute. Enumeral recently announced an agreement to place the system with Memorial Sloan-Kettering Cancer Center.
Enumeral to Present at Sachs Associates Cancer Bio Partnering & Investment Forum
Business Wire - Thu Feb 19, 7:01AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present at the Sachs Associates Cancer Bio Partnering & Investment Forum on February 23, 2015 at 12:00 p.m. EST. The meeting is being held at the New York Academy of Sciences in New York City.
Enumeral and Memorial Sloan Kettering Cancer Center to Research Cancer Immunology With Advanced Prototype System for Human Tissue Immuno-Oncology Profiling
Business Wire - Mon Jan 12, 7:02AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that the company signed an agreement with Memorial Sloan Kettering (MSK) Cancer Center as part of Enumeral's Phase II Small Business Innovation Research (SBIR) contract with the National Cancer Institute (NCI). Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed at MSK in the laboratory of Jedd D. Wolchok, M.D., Ph.D., Chief of Melanoma and Immunotherapeutics Service, Lloyd J. Old/Ludwig Chair in Clinical Investigation Department of Medicine and Ludwig Center, at Memorial Sloan Kettering Cancer Center. Dr. Wolchok played a critical role in the clinical development of ipilimumab and nivolumab, immunotherapies which represent a transformational advancement in the treatment of cancer.
Enumeral to Present at Upcoming Conferences in January
Business Wire - Thu Jan 08, 7:01AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present at the following conferences:
Harris & Harris Group Notes Publicly Traded Portfolio Company Enumeral Biomedical's Collaboration With Merck
GlobeNewswire - Mon Dec 22, 11:28AM CST
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes that its publicly traded portfolio company, Enumeral Biomedical Holdings, Inc., announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. Enumeral's human-driven immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response. Under the terms of the agreement, Enumeral will receive R&D funding and is eligible to receive undisclosed future milestone payments if certain goals are achieved. Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies. You may access Enumeral's press release at http://www.enumeral.com/news-events/pr-2014-12-18.php.
TINY: 2.16 (unch), MRK: 50.95 (-0.07)
Enumeral and Merck Form Collaboration for Predicting Clinical Drug Response with Human-driven Immune Profiling Platform
Business Wire - Thu Dec 18, 7:01AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), today announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck.
MRK: 50.95 (-0.07)
Enumeral: An Undiscovered And Undervalued Biotechnology Company
Tony Schwartz, PhD - at Seeking Alpha - Sat Dec 06, 7:00AM CST
